The EU Commission clears acquisition that creates global number two animal health company, subject to fix-it-first remedy including a technology transfer of vaccines (Boehringer Ingelheim / Sanofi)

KEYWORDS
References

EU Commission, Boehringer Ingelheim / Sanofi, Case No M.7919, 4 August 2016

EU Commission, Boehringer Ingelheim / Sanofi, Press Release, 4 August 2016

BOEHRINGER INGELHEIM/SANOFI ANIMAL HEALTH - THE TIMELY INJECTION OF A FIX-ITFIRST REMEDY* In a nutshell: The acquisition of Sanofi's animal health business by Boehringer Ingelheim led to competition concerns in a number of animal vaccine and pharmaceutical markets. The remedy put forward included a technology transfer of vaccines, a highly complex process which can lead to implementation risks. However the presence of a suitable purchaser fulfilling the strict criteria required to carry out a successful transfer, the robustness of the technologies to be transferred, and a thorough Phase 1 process made it possible for the Commission to approve a fix-it firstremedy in Phase 1. Overview In December 2015, Boehringer Ingelheim (BI, Germany) and Sanofi (France) decided to enter into an

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • European Commission - DG COMP (Brussels)
    Belgium 4 contributions 1273 visits
  • Sullivan & Cromwell LLP
    Belgium 1 contribution 266 visits

Quotation

Marion Bailly, Justin Gibbs, The EU Commission clears acquisition that creates global number two animal health company, subject to fix-it-first remedy including a technology transfer of vaccines (Boehringer Ingelheim / Sanofi), 4 August 2016, e-Competitions Pharma & Mergers, Art. N° 86501

Visites 266

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues